GIPR and obesity disorder: GLP-1-RA such as liraglutide [4], semaglutide [5], and the dual agonist tirzepatide [6], activating both the GLP1- and the gastric-inhibitory polypeptide receptor (GIP-R), have been shown to significantly reduce body weight, making them a promising therapeutic option for the treatment of obesity.